Loading news...
Guru Stock PicksFairholme Fund has made the following transactions:Reduce in JOE by 0.23%David Tepper has made the following transactions:Reduce in WHR by 18.41
Stock News Wall Street whipsawed by Mideast turmoil: The SPDR S&P 500 ETF Trust (SPY) fell Tuesday, then futures steadied as oil volatility and safeâhaven flo
Guru Stock PicksKen Fisher has made the following transactions:Reduce in DEO by 23.8%Sold out in VSHAdd in AMKR by 204.55%New position in BROChuck Royce has mad
Ark Invest bought shares of MercadoLibre, Intellia Therapeutics, and Generate Biomedicines on Monday. MercadoLibre and Intellia Therapeutics are trading 33% and 45% below their 52-week highs, respectively.
Stock News Hormuz disruption risks energy shock: Exxon Mobil (XOM) and global markets face rising supply risks as Iran claims to have shut the Strait of Hormuz;
One IPO and six SPACs came to market this past week, and one major issuer joined the pipeline as February comes to a close. One large IPO is currently scheduled in the week ahead, although some smaller issuers may join the calendar throughout the week. Street research is expected for seven companies in the week ahead, and one lock-up period will be expiring.
Flagship-backed Generate Biomedicines' shares fell 6.25% in its Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market volatility kept investors cautious toward new listings.
Drug developer Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares at $16 each.
SOMERVILLE, Mass., Feb. 26, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (Nasdaq: GENB) ("Generate"), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price of $16.00 per share.
Drug developer Generate Biomedicines said on Monday it was aiming to raise as much as $425 million in its initial public offering in the United States.
One small issuer and four blank check companies went public this past week as the IPO market continued to weather the recent volatility. No deals are currently on the calendar for the week ahead, although some small deals may join the calendar throughout the week, as the typical February lull takes hold of the IPO market while issuers work on year-end audited financials. Street research is expected for four companies in the week ahead, and four lock-up periods will be expiring.
Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout the week.
Generate Biomedicines is pursuing an IPO to fund its clinical trials and pipeline expansion efforts. GENB's lead asset, GB-0895, targets severe asthma and COPD, with Phase 3 enrollment expected to be completed by H2 2027. Strategic collaborations with Amgen and Novartis offer up to $2.9 billion in milestone potential, enhancing upside.